Salih Tünbekici

Gaziantep Dr Ersin Arslan Training and Research Hospital

H指数:4

被引数:45

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Is IMvigor011 a conventional adjuvant trial or a ctDNA-triggered preemptive treatment strategy?

IMvigor011是常规辅助试验还是ctDNA触发的预防性治疗策略？

Future Oncology

IF2.6

2026-10-070

PRE

Impact of adjuvant endocrine therapy on disease-free survival in early triple-positive breast cancer: a multicenter retrospective cohort study of the Turkish oncology group

三阴性乳腺癌患者辅助内分泌治疗对无病生存期的影响：土耳其肿瘤学组的回顾性多中心队列研究

BMC Cancer

IF3.4

2026-08-030

Mustafa Seyyar; Pervin Can Şancı; Akif Doğan; Sedat Biter; Tolga Köşeci; Onur Yazdan Balçık; Sinem Solmaz Karabel; Ali Kalem; Cengiz Akosman; Kezban Nur Pilancı; İlknur Deliktaş Onur; Ülkü Yalçıntaş Arslan; Yasemin Kemal; Tugay Avcı; Mustafa Şahbazlar; Seval Akay; Emir Gökhan Kahraman; Ayberk Bayramgil; Yunus Emre Altıntaş; Salih Tünbekici; Erdem Göker; Canan Çolak; Teyfik Demir; Güzin Demirağ; Gökçe Gül Güneysu; Musa Barış Aykan; İsmail Nazlı; Onur Alkan; İlker Nihat Ökten; Rumeysa Çolak; Mesut Yılmaz; Hasibe Bilge Gür; İlhan Hacıbekiroğlu; Müge Sönmez; Neslihan Özyurt; Okan Aydın; Kayhan Ertürk; Elif Şahin; Anıl Karakayalı; Ece Baydar; İlkay Çıtakkul; Gamze Emin; Atila Yıldırım; Ahmet Gülmez; Uğur Özberk; Efnan Algın; Çağlar Köseoğlu; Fatma Keskin Uzundere; Zuhat Urakçı; Melih Akpunar; Ali Alkan; Ali Süner; Pınar Peker; Yasemin Aydınalp Camadan; Lamia Şeker Can; Tuğba Akın Telli; Nargiz Majidova; Mehmet Uzun; Merve Kuday Özkan; Meltem Baykara; Halil Göksel Güzel; Hasan Çağrı Yıldırım; Umut Kefeli; Devrim Çabuk; Tulay Kus

Serum Carcinoembryonic Antigen Levels Across Molecular Subtypes and Their Clinical and Prognostic Implications in Metastatic Non-Small Cell Lung Cancer

血清癌胚抗原水平在转移性非小细胞肺癌分子亚型中的分布及其临床和预后意义

Medicina-Lithuania

IF2.4

2026-04-090

免疫相关不良事件作为接受帕博利珠单抗治疗的早期三阴性乳腺癌中病理完全缓解的预测因子

Immunotherapy

IF2.3

2026-04-011

PRE

Guren, Ali Kaan; Demircan, Nazim Can; Gumusay, Ozge; Simsek, Eda Tanrikulu; Kemik, Fatih; Karaoglu, Cagla; Sahin, Taha Koray; Tunbekici, Salih; Akkaya, Kubra; Guliyev, Murad; Gezici, Baris; Gur, Hasibe Bilge; Karakas, Delyadil; Unlu, Ahmet; Altunok, Oguz; Nazli, Ismail; Biter, Sedat; Kaya, Tugba; Yetginoglu, Ozge; Gunes, Tugce Kubra; Seker Can, Lamia; Majidova, Nargiz; Sever, Nadiye; Akkus, Aysun Fatma; Kara, Ismail Oguz; Ozturk, Banu; Deligonul, Adem; Kaplan, Muhammet Ali; Atag, Elif; Hacibekiroglu, Ilhan; Demirci, Nebi Serkan; Biricik, Fatih Selcuk; Guven, Deniz Can; Aksoy, Sercan; Arikan, Rukiye; Sari, Murat; Bayoglu, Ibrahim Vedat; Kostek, Osman

The effect of switching from ribociclib to palbociclib due to toxicity in hormone receptor-positive, HER2-negative metastatic breast cancer: a real-world, multicenter, retrospective study

因毒性作用将ribociclib换用palbociclib对激素受体阳性、HER2阴性转移性乳腺癌的影响：一项真实世界、多中心、回顾性研究

Scientific Reports

IF3.9

2026-03-260

OAAI

Real-world effectiveness and safety of brigatinib in advanced ALK-positive NSCLC: a nationwide multicenter study by the Turkish Oncology Group

brigatinib 在晚期ALK阳性NSCLC中的真实世界有效性与安全性：土耳其肿瘤学组进行的一项全国多中心研究

Clinical and Translational Oncology

IF2.5

2026-02-110

PRE

Salih Tunbekici; Hamit Bal; Oguzcan Kınıkoglu; Hayati Arvas; Harun Muglu; Ahmet Bilici; Mustafa Seyyar; Halil Goksel Guzel; Banu Ozturk; Ozge Yalıcı; Duygu Ozaskın; Ramazan Cosar; Fatmagul Cıkladılmez; Evrican Zin; Aytac Terzi; Tugce Ulaslı; Taha Koray Sahın; Denız Can Guven; Gamze Serın; Merve Bıyıklı Alemdar; Bilgin Demir; Ali Kalem; Pervin Can; Kazım Uygun; Elif Sahin; Teoman Sakalar; Ali Kaan Guren; Gokhan Ozturk; Enes Yesılbas; Tugce Kubra Gunes; Burcu Belen; Muzaffer Ugraklı; Kursat Dıslı; Ahmet Oruc; Melek Karakurt Eryılmaz; Ismet Culcuoglu; Mustafa Ersoy; Bahadır Koylu; Fatih Selcukbiricik; Oguzhan Yıldız; Mehmet Emın Yılmaz; Saadettin Kılıckap; Ertugrul Bayram; Caner Acar; Gokhan Sahin; Haydar Cagatay Yuksel; Mustafa Murat Mıdık; Pınar Gursoy; Erdem Goker

与健康相关的生活质量和免疫检查点抑制剂治疗长期存活者的心理社会结局：一项全国性多中心研究

Frontiers in Immunology

IF5.9

2025-12-100

Taha Koray Sahin; Fatih Atalah; Bahadir Koylu; Ahmet Oruc; Aydin Acarbay; Akgun Karakok; Sevgi Dogan; Cevat Ilteris Kikili; Görkem Turhan; Gamze Emin; Selahattin Celik; Ilknur Deliktas Onur; Tuba Ugur Tuzcu; Sedat Biter; Safa Can Efil; Fadime Sinem Ardic; Azer Gokmen; Halil Goksel Guzel; Kadri Turan; Ahmet Kürsad Disli; Salih Tunbekici; Erdem Goker; Mevlude Inanc; Ozlem Ozdemir; Banu Ozturk; Muslih Urun; Hatime Arzu Yasar; Mehmet Ali Nahit Sendur; Ismail Oguz Kara; Osman Sutcuoglu; Ozturk Ates; Tulay Eren; Atila Yildirim; Saadettin Kilickap; Omer Dizdar; Fatma Alev Turker; Mustafa Erman; Mehmet Artac; Fatih Selcukbiricik; Sercan Aksoy; Deniz Can Guven

Real-world comparison of doxorubicin–ifosfamide versus gemcitabine–docetaxel regimens in metastatic uterine leiomyosarcoma: a multicenter retrospective study

晚期子宫平滑肌肉瘤中多柔比星–异环磷酰胺与吉西他滨–多西他赛方案的真实世界比较：一项多中心回顾性研究

Discover Oncology

IF2.9

2025-11-170

OAAI

Salih Tunbekici; Gokhan Sahin; Haydar Cagatay Yuksel; Caner Acar; Imge Akın; Hasan Aslanhan; Mert Iscı; Ceren Kabaoglu; Hamit Bal; Abdullah Sakin; Alper Coskun; Mustafa Seyyar; Mehmet Sıddık Dilek; Mahmut Kara; Ali Solmaz; Teyfik Demir; Evrican Zin; Aytac Terzi; Fatih Kus; Ilgın Koc Kus; Zafer Arık; Ali Aytac; Özge Demirkıran; Bilgin Demir; Havva Yesil; Sedat Biter; Tolga Koseci; Ertugrul Bayram; Ahmet Unsal; Ahmet Ozveren; Alper Sevınc; Duygu Ozaskın; Meltem Baykara; Ahmet Unlu; Arıf Kus; Cengiz Karacin; Merih Yalcıner; Galip Can Uyar; Osman Sutcuoglu; Esmanur Kaplan; Teoman Sakalar; Elif Sahin; Gamze Emin; Atilla Yıldırım; Ceren Mordag; Irem ugurlu; Ilhan Hacıbekiroglu; Ibrahim Tunbekici; Pınar Gursoy; Ulus Ali Sanli; Erdem Goker

Association between immune-related adverse events and recurrence dynamics under adjuvant anti–PD-1 therapy in resected melanoma

免疫相关不良事件与辅助抗PD-1疗法下切除后黑色素瘤的复发动力学之间的关联

Frontiers in Oncology

IF3.3

2025-11-070

OAAI

Neoadjuvant Regimens and Their Impact on Adjuvant T-DM1 Outcomes in HER2-Positive Early Breast Cancer

HER2-Positive早期乳腺癌新辅助治疗方案及其对辅助T-DM1结局的影响

MEDICINA-LITHUANIA

IF2.4

2025-11-010

Real-world effectiveness and safety of sacituzumab govitecan in patients with metastatic or unresectable locally advanced triple-negative breast cancer: A multicenter study by the Turkish Oncology Group

曲拉妥单抗（sacituzumab govitecan）在伴有转移性或局部晚期不可切除的三阴性乳腺癌患者中的真实世界有效性与安全性：土耳其肿瘤学组（Turkish Oncology Group）开展的一项多中心研究

International Journal of Cancer

IF4.7

2025-10-280

PRE

Salih Tunbekici; Gokhan Sahin; Sercan Ön; Ahmet Oruc; Melek Karakurt Eryılmaz; Abdullah Sakin; Alper Coskun; Mustafa Seyyar; Fatma Keskin Uzundere; Erdem Kolemen; Devrim Cabuk; Safa Can Efil; Teyfik Demir; Emine Turkmen; Ferhat Ekinci; Aytac Terzi; Taha Koray Sahin; Deniz Can Guven; Sercan Aksoy; Ali Aytac; Özge Demirkıran; Bilgin Demir; Ismet Culcuoglu; Mustafa Ersoy; Esra Asarkaya; Ufuk Camanlı; Barıs Gezici; Ahmet Ozveren; Alper Sevınc; Sait Kitaplı; Ahmet Unlu; Banu Ozturk; Alper Turkel; Mutlu Dogan; Ferit Aslan; Enes Yesilbas; Esmanur Kaplan; Teoman Sakalar; Elif Sahin; Gamze Emin; Esra Asık; Atilla Yıldırım; Taliha Guclu; Irem ugurlu; Fatma Kahvecioglu; Ilhan Hacıbekiroglu; Ibrahim Tunbekici; Selami Bayram; Ali Osman Kaya; Nargiz Majidova; Ozge Yalıcı; Murat Karateke; Nilufer Avcı; Burcu Belen; Hamit Bal; Oguzcan Kınıkoglu; Fatma Paksoy Turkoz; Eda Tanrıkulu Sımsek; Oguz Altınok; Tugce Kubra Gunes; Yunus Emre Altıntas; Murad Guliyev; Gokhan Ozturk; Dilek Erdem; Yakup Duzkopru; Ali Inal; Ali Kaan Guren; Nilgun Yıldırım; Tugba Akın Telli; Yurdagul Danacı; Umut Aydın; Elvina Almuradova; Hasan Cagrı Yıldırım; Pınar Gursoy; Mehmet Ali Nahit Sendur; Erdem Goker

Efficacy and safety of doxorubicin–ifosfamide versus gemcitabine–docetaxel as first-line therapy in advanced nonuterine leiomyosarcoma: A multicenter real-world study

多中心真实世界研究：多柔比星–异环磷酰胺方案与吉西他滨–多西他赛方案作为一线疗法治疗晚期非子宫平滑肌肉瘤的疗效与安全性比较

International Journal of Cancer

IF4.7

2025-10-280

PRE

Salih Tunbekici; Gokhan Sahin; Haydar Cagatay Yuksel; Caner Acar; Imge Akın; Hasan Aslanhan; Mert Iscı; Ceren Kabaoglu; Hamit Bal; Abdullah Sakin; Alper Coskun; Mehmet Sıddık Dilek; Mahmut Kara; Ali Solmaz; Evrican Zin; Aytac Terzi; Fatih Kus; Ilgın Koc Kus; Zafer Arık; Ali Aytac; Özge Demirkıran; Bilgin Demir; Havva Yesil; Sedat Biter; Tolga Koseci; Ertugrul Bayram; Ahmet Unsal; Alper Sevınc; Duygu Ozaskın; Meltem Baykara; Ahmet Unlu; Arıf Kus; Cengiz Karacin; Galip Can Uyar; Osman Sutcuoglu; Esmanur Kaplan; Teoman Sakalar; Elif Sahin; Gamze Emin; Atilla Yıldırım; Ceren Mordag; Irem Ugurlu; Ilhan Hacıbekiroglu; Ibrahim Tunbekici; Ulus Ali Sanli; Erdem Goker; Pınar Gursoy

Real-world comparison of cabozantinib and sunitinib in advanced non-clear cell renal cell carcinoma: A multicenter study by the Turkish Oncology Group

卡博替尼与舒尼替尼在晚期非透明细胞肾细胞癌中的真实世界比较：土耳其肿瘤学集团的多中心研究

INTERNATIONAL JOURNAL OF CANCER

IF4.7

2025-09-010

PRE

Sahin, Gokhan; Tuzun, Esmanur Kaplan; Guzel, Halil G.; Guliyev, Murad; Disli, Ahmet K.; Yazici, Melike; Yildiz, Oguzhan; Gunes, Tugce K.; Alkan, Suleyman; Kahraman, Emir G.; Ozel, Gamze Serin; Icli, Mehmet C.; Sahin, Elif; Muglu, Harun; Acar, Caner; Tunbekici, Salih; Yuksel, Haydar C.; Yucel, Hakan; Kahya, Burcu Ulas; Kitapli, Sait; Buyuksimsek, Mahmut; Ipek, Suheda A.; Dama, Pinar E.; Usta, Ekin Akyildiz; Yilmaz, Mesut; Asik, Esra; Ozalp, Faruk R.; Savsar, Mehmet G.; Kocaaslan, Erkam; Sim, Saadet; Agaoglu, Ahmet B.; Camoz, Elif Sertesen; Demir, Teyfik; Uyar, Galip C.; Yildirim, Atila; Cinkir, Havva Y.; Salim, Derya Kivrak; Dogu, Gamze Gokoz; Alan, Ozkan; Bayram, Ertugrul; Karacin, Cengiz; Guc, Zeynep G.; Ekinci, Ferhat; Eryilmaz, Melek Karakurt; Semiz, Huseyin S.; Unal, Olcun U.; Goksu, Sema Sezgin; Ozturk, Banu; Inanc, Mevlude; Uygun, Kazim; Hacibekiroglu, Ilhan; Ercolak, Vehbi; Kara, Ismail O.; Yazici, Ozan; Bilici, Ahmet; Tanriverdi, Ozgur; Karaca, Burcak; Erman, Mustafa; Gokmen, Erhan; Goker, Erdem; Yildirim, Hasan Cagri

Dynamic blood-based biomarkers predict early response to ipilimumab and nivolumab in advanced melanoma

动态血液生物标志物可预测晚期黑色素瘤对伊匹木单抗和纳武利尤单抗的早期应答

clinical translational oncology

IF0

2025-08-210

PRE

The role of laboratory indices on treatment response and survival in breast cancer receiving neoadjuvant chemotherapy

实验室指标对乳腺癌新辅助化疗疗效和生存率的影响

SCIENTIFIC REPORTS

IF3.9

2024-05-275

OAAI